Whole blood platelet aggregometry in HIV-infected patients on treatment with abacavir

Muñoz, Rosario Palacios; Correa, José Antonio González; Ruiz, Josefa; Nuño, Enrique; Márquez, Manuel; Cruz, J. P. De La; Santos, Jesús

doi:10.4236/ojim.2012.22013

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both tests predict thromboembolic events and CVD in various clinical settings [14,15]. Few studies have addressed coagulopathy in HIV infection by functional haemostatic tests [16][17][18][19], and no previous studies have combined whole blood tests of primary and secondary haemostasis in HIV-infected individuals.…”

Section: Introductionmentioning

confidence: 98%

Discrepant coagulation profile in HIV infection

Haugaard

Lund²,

Birch³

et al. 2013

Aids

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 98%

Discrepant coagulation profile in HIV infection

Haugaard

Lund²,

Birch³

et al. 2013

Aids

View full text Add to dashboard Cite

show abstract

“…A study comparing whole blood platelet aggregation using MEA found hyporeactivity in both HIV-treated and untreated individuals [23], similar to findings by impedance aggregometry [24]. It is worth noting that co-infection with HBV (6 vs. 4%) and HCV (0 vs. 2%) and low CRP levels [23] could have obscured the overall response.…”

Section: Whole Blood Platelet Aggregometry-multiple Electrode Aggrego...mentioning

confidence: 57%

Challenges in Platelet Functions in HIV/AIDS Management

Ogweno¹

2023

Infectious Diseases

View full text Add to dashboard Cite

The interest in platelet functions in HIV/AIDS is due to the high incidence of microvascular thrombosis in these individuals. A lot of laboratory data have been generated regarding platelet functions in this population. The tests demonstrate platelet hyperactivity but decreased aggregation, though results are inconsistent depending on the study design. Antiretroviral treatments currently in use display complex interactions. Many studies on platelet functions in these patients have been for research purposes, but none have found utility in guiding drug treatment of thrombosis.

show abstract

“…Clinical studies have reported enhanced ex vivo platelet aggregation in PLWH compared with matched HIV‐negative controls (Satchell et al, ). Furthermore, ABC was associated with enhanced platelet aggregation compared to patients on alternative therapies (Satchell et al, ), including TDF, which had no effect (Munoz et al, ). There are contrasting reports demonstrating that ABC has no effect on platelet activation in response to ADP and collagen (Alvarez, Rios‐Navarro, et al, ; Diallo et al, ).…”

Section: Introductionmentioning

confidence: 99%

Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus‐associated cardiovascular risk

Taylor

Smyth

Rauzi

et al. 2019

British J Pharmacology

View full text Add to dashboard Cite

Background and purpose: Some clinical studies have reported increased myocardial infarction in people living with human immunodeficiency virus (HIV) taking the antiretroviral abacavir sulphate (ABC). Given that clinical studies contain confounding variables (e.g., HIV-associated factors), we investigated the pharmacological effects of antiretrovirals on platelet function in HIV-negative volunteers in order to identify mechanisms of increased cardiovascular risk.Experimental approach: Platelets were isolated from healthy volunteers and HIVnegative subjects enrolled on a Phase I clinical trial and platelet function evaluated using aggregometry and flow cytometry. In vivo platelet thromboembolism was monitored in anaesthetized mice.Key results: Human platelet aggregation was unaffected by all antiretrovirals tested, but ABC treatment led uniquely to increased platelet granule release. ABC also interrupted NO-mediated inhibition of platelet aggregation and increased in vivo aggregation in mice. Another antiretroviral, tenofovir, did not affect platelet function. Furthermore, aggregation and activation of platelets isolated from 20 subjects taking clinically relevant doses of tenofovir were comparable to baseline samples.Conclusions and implications: ABC can enhance platelet activation, independently of variables that confound clinical studies, suggesting a potential pharmacological effect that is absent with tenofovir. Mechanistically, we propose that ABC enhances platelet degranulation and interrupts NO-mediated platelet inhibition. The interaction of ABC with NO signalling is demonstrated by ABC-mediated enhancement of aggregation in vivo and in vitro that persisted in the presence of NO. Although an association between ABC and platelet activation has not been confirmed in patients, these findings provide evidence of a mechanistic link between platelet activation and antiretroviral therapy.

show abstract

Whole blood platelet aggregometry in HIV-infected patients on treatment with abacavir

Cited by 4 publications

References 25 publications

Discrepant coagulation profile in HIV infection

Discrepant coagulation profile in HIV infection

Challenges in Platelet Functions in HIV/AIDS Management

Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus‐associated cardiovascular risk

Contact Info

Product

Resources

About